Uniphar PLC · EURONEXT:UPR

Uniphar — Technical Presentation (October 2017)

15 slides from Uniphar's technical presentation, October 2017

  1. Slide 1: ProVen: Probiotics

    Slide 1: ProVen: Probiotics

    Webinar 11 ProVen: Probiotics

  2. Slide 2: Probiotic History

    Slide 2: Probiotic History

    ProVen Probiotic History Elie Metchnikoff (1845-1916)

  3. Slide 3: The Lab4 Consortium

    Slide 3: The Lab4 Consortium

    ProVen The Lab4 Consortium Lab4 consists of four specially selected types of friendly probiotic bacteria: • Lactobacillus acidophilus – strain 1 • Lactobacillus acidophilus – strain 2 • Bifidobacterium bifidum Lactobacillus acidophilus • Bifidobacterium animalis ( var lactis) Bifidobacterium bifidum

  4. Slide 4: Antibiotics and Associated Diarrhoea

    Slide 4: Antibiotics and Associated Diarrhoea

    ProVen Antibiotics and Associated Diarrhoea • AAD – common adverse event with global prevalence of AAD ranges from 3.2% to 29% • Among all AAD cases, 10-20% are associated with CDAD • There are about 2000 new cases of CDAD in Ireland annually. • Recurrence of CDAD occurs in approx. 30% of patients w

  5. Slide 5: A Review of Human Clinical Trials Performed with ProVen Probiotics Over the Last 12 Years

    Slide 5: A Review of Human Clinical Trials Performed with ProVen Probiotics Over the Last 12 Years

    ProVen A Review of Human Clinical Trials Performed with ProVen Probiotics Over the Last 12 Years

  6. Slide 6: Probiotics and Antibiotic Associated Diarrhoea (AAD)

    Slide 6: Probiotics and Antibiotic Associated Diarrhoea (AAD)

    ProVen Probiotics and Antibiotic Associated Diarrhoea (AAD) Overall effect RR = 0.58, Overall effect 95% CI 0.50-0.68 RR = 0.46, 95% CI 0.35-0.61

  7. Slide 7: Probiotics and Antibiotic Associated Diarrhoea (AAD)

    Slide 7: Probiotics and Antibiotic Associated Diarrhoea (AAD)

    ProVen Probiotics and Antibiotic Associated Diarrhoea (AAD) Trial type: Double blind placebo controlled Location: Addenbrookes Hospital U.K Aim: Use ProVen Adult to prevent or reduce Clostridium difficile infection and associated diarrhoea in patients receiving antibiotics. Trial Design:  150 patie

  8. Slide 8: The Cambridge Clostridium difficile AAD Study

    Slide 8: The Cambridge Clostridium difficile AAD Study

    ProVen The Cambridge Clostridium difficile AAD Study RCT with 150 patients initiating antibiotic therapy were randomly assigned to probiotic 1 capsule daily or placebo group for 20 days. Outcomes 1) Incidence of C.difficile: Placebo: 13.0% ProVen: 15.9% 2) Incidence of C.difficile toxin: Placebo: 78

  9. Slide 9: The Cambridge Lab4 Antibiotic Trial - Opportunistic Pathogen Re-growth

    Slide 9: The Cambridge Lab4 Antibiotic Trial - Opportunistic Pathogen Re-growth

    ProVen The Cambridge Lab4 Antibiotic Trial 1 - Opportunistic Pathogen Re-growth Following Antibiotic Therapy To investigate the following: • Effects of antibiotics on re-growth of opportunistic pathogens • Effects of probiotics on this opportunistic pathogen re-growth • Two capsules of ProVen Adult

  10. Slide 10: Cambridge Lab4 trial

    Slide 10: Cambridge Lab4 trial

    ProVen Cambridge Lab4 trial 1 Group Days Treatment 1–7 Antibiotic/Placebo 1 8 – 15 Placebo 1–7 Antibiotic/Placebo 2 8 – 15 Lab 4 1–7 Antibiotic /Lab4 3 8 – 15 /Lab4 Samples: Days 1 (control), 7, 12, 17 and 28

  11. Slide 11: Effects of Antibiotics and ProVen on Enterobacter, Enterococcal and Staphylococcal Populations

    Slide 11: Effects of Antibiotics and ProVen on Enterobacter, Enterococcal and Staphylococcal Populations

    ProVen Populations Effects of Antibiotics and ProVen Probiotics on the Population of Enterobacter, Enterococcal and Staphylococcal Madden et al 2005, Int Immunopharm 5; 1091-97

  12. Slide 12: Cambridge Antibiotic Resistance Trial

    Slide 12: Cambridge Antibiotic Resistance Trial

    ProVen Cambridge Antibiotic Resistance Trial 2 Effect of ProVen on Antibiotic Resistance in the Re-growth Microbiota The emergence of antimicrobial drug resistance adversely affects patient care and threatens the management of public health infectious diseases globally. (WHO World Health Report 2007

  13. Slide 13: Cambridge Antibiotic Resistance Trial – Results

    Slide 13: Cambridge Antibiotic Resistance Trial – Results

    ProVen Cambridge Antibiotic ResistanceTrial – Results • The types measured were the Enterobacteria • At the start, about 18% of patients had detectable levels of antibiotic resistant Enterobacteria • After the trial, the control group 100% of patients developed detectable levels of antibiotic resist

  14. Slide 14: Probiotics and the Treatment of IBS

    Slide 14: Probiotics and the Treatment of IBS

    ProVen Probiotics and the Treatment of IBS Antibiotics Overall effect RR = 0.79 (95% CI: 0.70-0.89) Microbiota dysbiosis Probiotics (composition/activity) IBS development

  15. Slide 15: Summary Results of Sheffield LAB4 IBS Trial

    Slide 15: Summary Results of Sheffield LAB4 IBS Trial

    ProVen Summary Results of Sheffield LAB4 IBS Trial Significant reduction of Total IBS Symptoms comprising: The end of supplementation • number of days with pain • severity of pain • bloating Placebo • satisfaction with bowel habit Symptoms • quality of life Total IBS * Lab4 Probiotic * • Significant

Source: Internet Archive copy of uniphar.ie

More decks from Uniphar PLC

All 29 Uniphar decks